Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Replimune Group Inc (REPL)

Replimune Group Inc (REPL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 854,528
  • Shares Outstanding, K 68,417
  • Annual Sales, $ 0 K
  • Annual Income, $ -215,790 K
  • EBIT $ -232 M
  • EBITDA $ -241 M
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.15

Options Overview Details

View History
  • Implied Volatility 132.01% ( +48.47%)
  • Historical Volatility 105.17%
  • IV Percentile 78%
  • IV Rank 34.18%
  • IV High 316.04% on 05/21/24
  • IV Low 36.44% on 10/01/24
  • Put/Call Vol Ratio 3.23
  • Today's Volume 93
  • Volume Avg (30-Day) 290
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 4,125
  • Open Int (30-Day) 3,610

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.71
  • Number of Estimates 5
  • High Estimate -0.68
  • Low Estimate -0.73
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +7.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +13.55%
on 11/21/24
17.00 -26.53%
on 11/22/24
+1.26 (+11.22%)
since 11/20/24
3-Month
9.94 +25.65%
on 10/15/24
17.00 -26.53%
on 11/22/24
+1.58 (+14.48%)
since 09/20/24
52-Week
4.92 +153.86%
on 05/29/24
17.00 -26.53%
on 11/22/24
+5.03 (+67.43%)
since 12/20/23

Most Recent Stories

More News
Replimune Announces Pricing of Upsized Public Offering

REPL : 12.49 (+4.00%)
Replimune Group, Inc. Announces Proposed Public Offering of $125 Million in Common Stock and Pre-Funded Warrants

Replimune Group announced a proposed $125 million public stock offering, with an option for an additional $18.75 million.Quiver AI SummaryReplimune Group, Inc., a clinical stage biotechnology company specializing...

REPL : 12.49 (+4.00%)
Replimune Announces Proposed Public Offering

REPL : 12.49 (+4.00%)
Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat

Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.

IBB : 132.73 (+1.16%)
REPL : 12.49 (+4.00%)
XBI : 91.28 (+1.64%)
Replimune Group, Inc. Submits Biologics License Application for RP1 in Combination with Nivolumab for Advanced Melanoma Treatment

Replimune submitted a BLA to the FDA for RP1 with nivolumab, receiving Breakthrough Therapy designation for melanoma treatment.Quiver AI SummaryReplimune Group, Inc. announced the submission of a biologics...

REPL : 12.49 (+4.00%)
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

REPL : 12.49 (+4.00%)
Insider Sale: Chief Medical Officer of $REPL (REPL) Sells 7,246 Shares

Konstantinos Xynos, the Chief Medical Officer of $REPL ($REPL), sold 7,246 shares of the company on 11-18-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

REPL : 12.49 (+4.00%)
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

REPL : 12.49 (+4.00%)
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

REPL : 12.49 (+4.00%)
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REPL : 12.49 (+4.00%)

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United...

See More

Key Turning Points

3rd Resistance Point 14.82
2nd Resistance Point 13.93
1st Resistance Point 13.21
Last Price 12.49
1st Support Level 11.60
2nd Support Level 10.71
3rd Support Level 9.99

See More

52-Week High 17.00
Last Price 12.49
Fibonacci 61.8% 12.39
Fibonacci 50% 10.96
Fibonacci 38.2% 9.53
52-Week Low 4.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar